Clinical Trial Detail

NCT ID NCT02259582
Title A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors OncoMed Pharmaceuticals, Inc.

lung non-small cell carcinoma


Carboplatin + Pemetrexed Disodium


Age Groups: adult

Additional content available in CKB BOOST